CoherusBioSciences, Inc. (CHRS) stock prices were up by 3.53% shortly after market trading commenced on June 4th, 2021, bringing the price per share up to USD$13.50 early on in the trading day.
The company recently announced the successful results from its pivotal study, JUPITER-02, which was a randomized, double-blind, placebo-controlled Phase 3 clinical trial. The trial was designed to evaluate toripalimub in conjunction with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC)
The interim analysis reported the meeting of the study’s primary endpoint, thereby demonstrating a progression-free survival (PFS) that showed statistically significant and clinically meaningful improvement as compared to chemotherapy alone. The study also met its secondary endpoints of PFS, as assessed by the assigned investigator, and objective response rate (ORR) data assessed by BIRC.
Results of the Analysis
Duration of response exhibited longer times and there was a higher disease control rate, as well as higher one- and two-year survival rates or the arm of the study that was administered toripalimab. The safety profile of the company’s treatment consolidated previous findings that established its safety in the clinical trials for toripalimab.
ASCO 2021 saw more than 30 abstracts for toripalimab bring accepted, two of which were selected for oral presentations. These abstracts describe the antitumor activities derived from observations of various cancers of the nasopharynx, skin, lung, esophagus, stomach, liver, biliary duct, head and neck, and pancreas. Pertinently, ten of the abstracts accepted indicated CHRS’s treatment’s potential in perioperative, adjuvant, or neoadjuvant treatment settings.
Scope of Toripalimab
Concurrent with the conducting of the JUPITER-02 trial, the annual ASCO meeting will see the presenting of various other studies of toripalimab. These results will support the existing development strategy, such as perioperative immunotherapy in patients who are found to have multiple solid tumors, including mucosal melanoma, esophageal cancer, gastric cancer, liver cancer, and non-small cell lung cancer. Furthermore, the results will facilitate the exploration of toripalimab for the treatment of ICC, checkpoint inhibitors for which have not yet been approved for use.
Future Outlook for CHRS
Armed with the success of its positive topline data and reaching primary and secondary endpoints, CHRS is poised to capitalize on the gain in momentum to push for the commercialization of the treatment. Current and potential investors are hopeful that the management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.